Lek will invest US$400 million for the construction of an advanced biopharmaceutical production centre in Slovenia, Europe.
The facility will feature cutting-edge production and storage facilities, with a combined surface area totalling 40,000 square metres.
The first of three facilities planned at Lek's current site in Lendava will be dedicated to producing energy products for the ongoing production while also addressing the future centre's demands for the production of drug substances used in biosimilars.
The new biosimilars production centre will enhance manufacturing capabilities and provide crucial support to propel the future expansion of the global biosimilar portfolio.
Once fully operational, the site will play a vital role in producing the necessary drug substances for biosimilars, catering to the treatment needs of patients in the areas of rheumatology, oncology, and immunology.
The facility is anticipated to commence operations by the end of 2026.
Type New Construction
Budget US$400 million